lol646 code free ios

lol646 code free ios Kevin Scheef calls out during Wahoo's Class C-1 boys basketball state tournament game last march at Pinnacle Bank Arena. One of the most successful high school boys basketball coaches in the state is no longer with his program. Kevin Scheef, who won three state championships and nearly 80% of his games at Wahoo, tendered his resignation at Monday night's meeting of the Wahoo school board. The minutes from that meeting are not yet public, but the agenda for Monday's meeting included an item that read "discuss, consider, and take any necessary action on accepting the resignation of Kevin Scheef." Scheef had not been on the bench for any of Wahoo's first four games for what the school termed a "personnel matter". Scheef is listed on the Wahoo public schools website as a business and technology teacher. Junior varsity coach Mike Bomar has served as the interim head coach for Wahoo's first four games. People are also reading... Wahoo is one of the state's most tradition-rich programs, with 12 state titles. The most recent championship came last season in Class C-1. Reach the writer at (402) 473-7436 or cbasnett@journalstar.com . On Twitter @ChrisBasnettLJS. .​ Get in the game with our Prep Sports Newsletter Sent weekly directly to your inbox! Assistant sports editor/high schools {{description}} Email notifications are only sent once a day, and only if there are new matching items.The Director of Elections for the Ablekuma North constituency, Daniel Yaw Tornyigah, has vowed to take legal action if the Electoral Commission (EC) attempts to overturn the earlier declaration of Ewura Abena Aubyn as the duly elected Member of Parliament (MP) for the area. In a press conference, Tornyigah reiterated that the NDC’s victory in Ablekuma North was the result of hard work and vigilance, reflecting the will of more than 70,000 voters. He emphasized that the party would not accept any attempt to reverse the decision made by the electorate. Tornyigah expressed concerns over the recent coalition of seven constituencies out of nine, which were declared for the NPP by the EC, raising questions about the commission’s impartiality. He accused the EC of potentially favoring the NPP, casting doubt on the transparency and fairness of the process. “We urge the Electoral Commission to uphold the principles of transparency, accountability, and fairness. The people of Ablekuma North deserve nothing less. We are committed to protecting this mandate and will legally challenge any effort to subvert the people’s choice,” Tornyigah stated.

Taylor Swift makes surprise visit to Kansas City children's hospital

Levis throws 2 TD passes to help Titans outlast Texans 32-27BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (" Neuphoria ” or the " Company ”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited's proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time (December 24, 2024 Sydney time). The shares of common stock of Neuphoria (" Neuphoria Shares ”) issued today in connection with the re-domiciliation are expected to commence trading on The Nasdaq Stock Market LLC under the symbol "NEUP” on December 24, 2024 or as soon as possible thereafter. In addition, Neuphoria will issue options to acquire shares of common stock in Neuphoria (" Neuphoria Options ”) to holders of options to acquire shares in Bionomics (" Bionomics Options ”) that were issued by Bionomics, in exchange for their Bionomics Options. Neuphoria will also issue a warrant to purchase 1,054,381 shares of common stock in Neuphoria (" Neuphoria Warrant ”) to an institutional investor that holds a warrant to purchase 12,652,572 American Depositary Shares ("ADSs”) of Bionomics (" Bionomics Warrant ”), in exchange for the Bionomics Warrant. Further details regarding the implementation of the redomiciliation can be found in a Current Report on Form 8-K that will be filed by Neuphoria with the SEC. Neuphoria (Nasdaq: NEUP) is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, "as needed” treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, Neuphoria has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions. Neuphoria's pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage. Forward-Looking Statements Neuphoria cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may,” "could,” "will,” "would,” "should,” "expect,” "plan,” "anticipate,” "believe,” "estimate,” "intend,” "predict,” "seek,” "contemplate,” "potential,” "continue” or "project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business and other risks described in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Neuphoria undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Neuphoria's filings with the SEC, copies of which are available from the SEC's website (www.sec.gov) and on Neuphoria's website (www.neuphoriatx.com) under the heading "Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Neuphoria expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release. Not an offer of securities This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction. The Neuphoria Shares, Neuphoria Options and Neuphoria Warrant have not been registered under the US Securities Act and may not be offered or sold except in a transaction registered under the US Securities Act or in a transaction exempt from such registration requirements and applicable US state securities laws.

Shoppers bemused as Easter eggs hit shop shelves before New Year’s Eve

Trader Up 900% In 11 Months Is Watching These Two Hot Growth Stocks Very CloselySITE (Society for Incentive Travel Excellence) Nominates Creative Group Canada for Prestigious Crystal Award SCHAUMBURG, Ill. , Dec. 18, 2024 /PRNewswire/ -- Creative Group, Inc., a full-service meeting, event, and incentive agency, was recently nominated for a Crystal Award in the category of Most Creative Solution Deployed to Overcome Adversity when war broke out in Israel . THE STORY Janet Traphagen, President of Creative Group, said, "I am so proud of our internal associates and our client's collaboration – the way they quickly pivoted to a new solution during a time of crisis was nothing short of amazing." The client and the qualifiers were thrilled with the newly designed travel experience and the creative thinking involved in bringing this alternative solution to life in such a short timeframe. THE IMPACT About Creative Group Creative Group is a full-service meeting, event, and incentive agency that delivers business results by inspiring people to thrive. An industry leader, Creative Group has been honored with numerous Society for Incentive Travel Excellence (SITE) awards and the CMI 25 Award, which recognizes the top 25 most influential meeting and incentive management companies in the U.S. Creative Group was founded in 1970, and has served clients in financial services, life sciences, insurance, manufacturing, retail, technology, automotive, and hospitality. Employing 220+ people, the company is headquartered in Schaumburg, Illinois , and maintains offices in San Francisco , Appleton, Wisconsin , and Toronto, Canada . For more information about Creative Group, visit http://www.creativegroupinc.com About the SITE Crystal Awards Recognition Program: Considered the highest honor in the incentive travel industry, the SITE Crystal Awards recognize creative, practical and truly memorable incentive programs that not only keep employees engaged but also drive business results and improve the bottom line. View original content to download multimedia: https://www.prnewswire.com/news-releases/creative-group-nominated-for-site-2025-crystal-award-for-most-creative-solution-deployed-to-overcome-adversity-302335550.html SOURCE Creative Group, Inc.